Managing Relapse in MS – Strategies for Switching
Therapy after Inadequate Response to Previous
Treatment Regimens

New Horizons in the Treatment and Management of Multiple Sclerosis is a 7-part live webinar
series that will provide attendees with the latest information in MS management.

This is Part 2 of the series focusing on Strategies for Switching Therapy in MS treatment.
This activity is an archive from the webinar held December 14, 2016
 
This activity is valid from January 31, 2017 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie, Bayer HealthCare, Biogen, Novartis Pharmaceuticals and Sanofi Genzyme

Description:
Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. As part of a multi-part webinar program this session will focus on managing relapse and switching therapy. It is critical that HCPs who will be in attendance for the live webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.

Upon Completion of this activity, participants will be able to:

  • Discuss key recent data on the efficacy and safety of current and emerging therapies for relapsing MS

  • Review patient, disease, and treatment characteristics that factor into relapsing MS treatment selection and considerations for predicting treatment response and identifying when to switch therapies

  • Review the role of teriflunomide and alemtuzumab in the management of relapsing MS

  • Discuss the role of interferon beta-1b in the management of relapsing MS
     

Faculty: Ronald Murray, MD, FAAN
Director
MS Clinic of Colorado

Disclosure:

Dr. Murray receives grants/research support from Acorda Therapeutics, Biogen, Genentech, Genzyme, Novartis, and Teva Pharmaceuticals. He also serves on the speaker’s bureau for Biogen, Genyzyme, and Teva Pharmaceuticals. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AbbVie, Bayer HealthCare, Biogen, Novartis Pharmaceuticals and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue